AF
HRTX icon

Amalgamated Financial’s Heron Therapeutics HRTX Stock Holding History

Amalgamated Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$86K Buy
+15,043
New +$110K ﹤0.01% 2202

Other funds holding HRTX

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Amalgamated Financial's HRTX Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Heron Therapeutics (HRTX) in Q1 2022: 15,043 shares worth $86K. The stake represents ﹤0.01% of the portfolio and ranks #2202 among its holdings.

186 funds tracked by Wall St. Rank hold HRTX as of Q1 2022.

  • Amalgamated Financial held 15,043 shares of Heron Therapeutics worth $86K as of Q1 2022.
  • Heron Therapeutics was a new Amalgamated Financial position in Q1 2022.
  • Heron Therapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2202 holding.
  • 186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.